The safety and tolerability of epacadostat alone and in combination with pembrolizumab in patients with advanced solid tumors: results from a first-in-Japanese phase I study (KEYNOTE-434)

被引：0
|
作者：
Toshihiko Doi
Yutaka Fujiwara
Kohei Shitara
Toshio Shimizu
Kan Yonemori
Nobuaki Matsubara
Izumi Ohno
Takahiro Kogawa
Yoichi Naito
Lance Leopold
Mihaela Munteanu
Naoyoshi Yatsuzuka
Shi Rong Han
Ayman Samkari
Noboru Yamamoto
机构：
[1] National Cancer Center Hospital East,Department of Experimental Therapeutics
[2] National Cancer Center Hospital,Department of Experimental Therapeutics
[3] Mitsui Memorial Hospital,Department of Respiratory Medicine
[4] Incyte Corporation,Department of Clinical Oncology
[5] Clinical Development,undefined
[6] MSD K.K. Oncology Science Unit,undefined
[7] Merck & Co.,undefined
[8] Inc.,undefined
来源：
Investigational New Drugs | 2021年 / 39卷
关键词：
Advanced solid tumors; Epacadostat (INCB024360); Japanese; Pembrolizumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：152 / 162
页数：10
相关论文
共 50 条
  • [21] A phase I and pharmacokinetic study of taladegib, a Smoothened inhibitor, in Japanese patients with advanced solid tumors
    Hideki Ueno
    Shunsuke Kondo
    Shusuke Yoshikawa
    Koichi Inoue
    Valérie Andre
    Masaomi Tajimi
    Haruyasu Murakami
    Investigational New Drugs, 2018, 36 : 647 - 656
  • [22] A phase I study of binimetinib (MEK162) in Japanese patients with advanced solid tumors
    Watanabe, K.
    Otsu, S.
    Hirashima, Y.
    Morinaga, R.
    Nishikawa, K.
    Hisamatsu, Y.
    Shimokata, T.
    Inada-Inoue, M.
    Shibata, T.
    Takeuchi, H.
    Watanabe, T.
    Tokushige, K.
    Maacke, H.
    Shiaro, K.
    Ando, Y.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (06) : 1157 - 1164
  • [23] A phase I study of binimetinib (MEK162) in Japanese patients with advanced solid tumors
    K. Watanabe
    S. Otsu
    Y. Hirashima
    R. Morinaga
    K. Nishikawa
    Y. Hisamatsu
    T. Shimokata
    M. Inada-Inoue
    T. Shibata
    H. Takeuchi
    T. Watanabe
    K. Tokushige
    H. Maacke
    K. Shiaro
    Y. Ando
    Cancer Chemotherapy and Pharmacology, 2016, 77 : 1157 - 1164
  • [24] A phase I and pharmacokinetic study of taladegib, a Smoothened inhibitor, in Japanese patients with advanced solid tumors
    Ueno, Hideki
    Kondo, Shunsuke
    Yoshikawa, Shusuke
    Inoue, Koichi
    Andre, Valerie
    Tajimi, Masaomi
    Murakami, Haruyasu
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (04) : 647 - 656
  • [25] Phase 1 dose escalation study of FGFR4 inhibitor in combination with pembrolizumab in advanced solid tumors patients
    Xu, Jianming
    Cui, Jiuwei
    Jiang, Haiping
    Zeng, Yan
    Cong, Xiuyu
    CANCER MEDICINE, 2023, 12 (07): : 7762 - 7771
  • [26] Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: Results from the phase 2 KEYNOTE-158 study
    Shapira-Frommer, Ronnie
    Mileshkin, Linda
    Manzyuk, Ludmila
    Penel, Nicolas
    Burge, Matthew
    Piha-Paul, Sarina A.
    Girda, Eugenia
    Martin, Jose A. Lopez
    Van Dongen, Marloes G. J.
    Italiano, Antoine
    Xu, Lei
    Jin, Fan
    Norwood, Kevin
    Ott, Patrick A.
    GYNECOLOGIC ONCOLOGY, 2022, 166 (02) : 211 - 218
  • [27] Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studies
    Moreno, V
    Calvo, E.
    Middleton, M. R.
    Barlesi, F.
    Gaudy-Marqueste, C.
    Italiano, A.
    Romano, E.
    Marabelle, A.
    Chartash, E.
    Dobrenkov, K.
    Zhou, H.
    Connors, E. C.
    Zhang, Y.
    Wermke, M.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (12) : 2985 - 2998
  • [28] Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studies
    V. Moreno
    E. Calvo
    M. R. Middleton
    F. Barlesi
    C. Gaudy-Marqueste
    A. Italiano
    E. Romano
    A. Marabelle
    E. Chartash
    K. Dobrenkov
    H. Zhou
    E. C. Connors
    Y. Zhang
    M. Wermke
    Cancer Immunology, Immunotherapy, 2022, 71 : 2985 - 2998
  • [29] Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study
    Saka, Hideo
    Kitagawa, Chiyoe
    Kogure, Yoshihito
    Takahashi, Yasuo
    Fujikawa, Koshi
    Sagawa, Tamotsu
    Iwasa, Satoru
    Takahashi, Naoki
    Fukao, Taro
    Tchinou, Catherine
    Landers, Donal
    Yamada, Yasuhide
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (04) : 451 - 462
  • [30] Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study
    Hideo Saka
    Chiyoe Kitagawa
    Yoshihito Kogure
    Yasuo Takahashi
    Koshi Fujikawa
    Tamotsu Sagawa
    Satoru Iwasa
    Naoki Takahashi
    Taro Fukao
    Catherine Tchinou
    Dónal Landers
    Yasuhide Yamada
    Investigational New Drugs, 2017, 35 : 451 - 462
12345